Commentary: How small is small?

International Journal of Epidemiology

Volumn 38, Issue 1, 2009, Pages 274-275

  Day, Nicholas ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN;

CHRONIC DISEASE; COHORT ANALYSIS; DISEASE CLASSIFICATION; EFFECT SIZE; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOME ANALYSIS; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HEREDITY; HUMAN; MEASUREMENT ERROR; NOTE; POPULATION GENETICS; PRIORITY JOURNAL; RISK ASSESSMENT; SAMPLE SIZE;

DISEASE; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; GENOTYPE; HUMANS; RESEARCH DESIGN; SAMPLE SIZE;

EID: 60149091353     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyn232     Document Type: Note

References (6)

1. Burton PR, Hansell AL, Fortier I et al. Size matters: Just how big is BIG?: Quantifying realistic sample size requirements for human genome epidemiology. Int J Epidemiol 2009;38:263-73.
2. HLA and Disease 1976. INSERM Publication No. 58.
3. Kissmeyer-Nielsen F (ed.). Histocompatibility Testing. Copenhagen: Munksgaard, 1975.
4. Chan SH, Day NE, Kunaratnam N, Chia KB, Simons MJ. HLA and nasopharyngeal cancer in Chinese: A further study. Int J Cancer 1983;32:171-76.
5. Pharoah PDP, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BAJ. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 2002;31:33-36.
6. SEARCH Study Collaborative Group. Genome-wide study finds SLCO1B1 variants strongly linked to statin-induced myopathy. N Engl J Med 2008;359:789-99.